UpStream Bio Inc. Stock Price, News & Analysis

Upstream Bio (Nasdaq: UPB) announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK. The presentation will showcase translational pharmacology modeling data for their drug verekitug, which targets the TSLP receptor for inflammatory diseases, particularly severe respiratory disorders. The data demonstrates verekitug's enhanced potency compared to treatments targeting the TSLP ligand, such as tezepelumab. Dr. Ashish Kalra, VP of Translational Research, will present these findings on June 15, 2025, focusing on the in silico system pharmacology modeling insights that explain the drug's superior potency mechanism.

Upstream Bio (Nasdaq: UPB), a clinical-stage biotech company focused on developing treatments for inflammatory diseases and severe respiratory disorders, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. CEO Rand Sutherland will engage in a fireside chat on June 11, 2025, at 9:20 a.m. ET. The presentation will be accessible via live webcast in the Events section of the company's Investors page, with a replay available afterward.

Upstream Bio (Nasdaq: UPB) has appointed Stacy Price as Chief Technology Officer. Price brings over 25 years of experience in technical operations, manufacturing, and product development in biotechnology. In her new role, she will oversee technical operations and product development expansion for verekitug, focusing on CMC processes and drug delivery.

Price previously served as Chief Technology and Manufacturing Officer at Invivyd and Chief Technical Officer at Akouos. She also held senior leadership positions at Ziopharm Oncology, Shire, and Transkaryotic Therapies. Price holds an M.S. in Biochemical Engineering and a B.S. in Chemical Engineering from Tufts University.

Upstream Bio (NASDAQ: UPB) reported its Q1 2025 financial results and accelerated guidance for its clinical programs. The company is developing verekitug, the only monoclonal antibody targeting the TSLP receptor in clinical development. Key updates include: top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps expected in Q3 2025, Phase 2 data for severe asthma now anticipated in H1 2026, and first patient dosing in COPD trial expected mid-2025. Financially, Upstream reported cash position of $431.4M expected to fund operations through 2027. Q1 2025 showed R&D expenses of $25.8M (up from $11.7M in Q1 2024) and a net loss of $27.3M (compared to $10.9M in Q1 2024). The company completed enrollment for its CRSwNP Phase 2 trial in January 2025, with patients receiving 100mg verekitug or placebo every 12 weeks over 24 weeks.

Upstream Bio (Nasdaq: UPB) has reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical programs. The company completed enrollment for its Phase 2 trial of verekitug in chronic rhinosinusitis with nasal polyps (CRSwNP), with top-line data expected in H2 2025.

Financial highlights include a successful upsized IPO raising $293 million in gross proceeds, with cash reserves of $470.5 million as of December 31, 2024, extending runway through 2027. Q4 2024 showed R&D expenses of $21.8 million (up from $11.6 million in Q4 2023) and G&A expenses of $5.2 million (up from $3.2 million in Q4 2023). Net loss increased to $21.2 million compared to $11.8 million in Q4 2023.

The company is advancing verekitug development in multiple respiratory diseases, including severe asthma (Phase 2 data expected H2 2026) and COPD (first patient dosing expected H2 2025).

Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases with an emphasis on severe respiratory disorders, has announced its participation in two major investor conferences in March 2025.

CEO Rand Sutherland, MD, will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Tuesday, March 4, 2025, from 11:50 a.m. to 12:20 p.m. ET. He will also present at the Leerink Partners Global Biopharma Conference 2025 in Miami, FL on Wednesday, March 12, 2025, from 1:40 p.m. to 2:10 p.m. ET.

Interested parties can access a live webcast of the presentations under the "Events" tab on the "Investors" page of the company's website on the day of each event. Replays of the webcasts will be available on the company's website following the presentations.

Upstream Security released its 2025 Automotive & Smart Mobility Cybersecurity Report, revealing alarming trends in automotive cybersecurity. The report shows that 60% of cyber incidents in 2024 affected thousands to millions of mobility assets, with massive-scale attacks more than tripling from 5% to 19% year-over-year.

Key findings include a surge in mobility-specific ransomware attacks, with 108 reported ransom attacks and 214 data breaches in 2024. A notable incident involved a US software provider serving 15,000 automotive dealerships, causing $1.02 billion in estimated losses. The total number of incidents reached 409 in 2024, up from 295 in 2023, with 92% of attacks executed remotely and 85% being long-range attacks.

Data and privacy-related incidents rose by 20% to account for 60% of all cases, while car system manipulation incidents increased to over 35%. The report emphasizes that current regulatory measures are insufficient to address the growing cyber risks in the automotive sector.

Upstream Bio (Nasdaq: UPB), a clinical-stage company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Rand Sutherland, MD, MPH, will deliver a presentation on Monday, January 13, 2025, at 2:15 p.m. PT.

The presentation will be accessible via live webcast through the 'Events' tab on the 'Investors' section of Upstream Bio's website. For those unable to attend the live session, a replay will be made available on the company's website following the presentation.

Upstream Bio (Nasdaq: UPB) has appointed Allison Ambrose as General Counsel, bringing over 15 years of experience in legal leadership. Ambrose, who previously served as General Counsel at Skyhawk Therapeutics and held leadership roles at Ginkgo Bioworks and Orchard Therapeutics, will oversee all legal functions and join the executive team.

The appointment comes at a important time for Upstream Bio, a clinical-stage company focused on developing treatments for inflammatory diseases, particularly verekitug for severe respiratory disorders. Ambrose's expertise spans corporate governance, securities law, compliance, and capital markets transactions, which will be valuable as the company advances its development programs as a newly public entity.